Retractable Technologies, Inc. (NYSE: RVP) reported net income of $2.8 million for the three months ended June 30, 2026, translating to earnings per share of $0.09. The profitability shift was driven entirely by a non-operating item: a $6.4 million realized gain from the sale of equity securities in the second quarter. Excluding this gain, the company recorded an operating loss of $5.1 million, identical to the operating loss posted in Q2 2025.

Total net sales declined significantly to $7.2 million (reported as $7.201 million) in Q2 2026, down from $10.4 million ($10.400 million) in the same period of 2025, a decrease of 30.8% (30.76%). The revenue contraction reflects a broader slowdown in unit sales, which fell 36.4% overall, primarily due to decreased demand for EasyPoint needle products. For the first half of 2026, net sales totaled $14.4 million, compared to $18.7 million in H1 2025, with cumulative operating losses widening to $11.3 million from $9.8 million.

What the Numbers Show

The divergence between the bottom-line result and operational performance is stark. The $2.8 million net profit masks a persistent operational deficit, as the $6.4 million one-time gain more than doubled the quarterly operating loss of $5.1 million. This indicates that core business operations remain unprofitable, with earnings power currently dependent on asset liquidation rather than revenue generation or cost efficiency improvements.

Revenue and Sales Dynamics

Domestic markets, which account for the majority of revenue, saw significant declines. Domestic revenues fell 30.8% year-over-year, while domestic unit sales dropped 35.1%. Domestic sales represented 81.6% of total revenues in Q2 2026, slightly up from 81.3% in Q2 2025. The company attributed the decrease in domestic sales to timing fluctuations in EasyPoint product orders from certain customers.

International revenues also contracted, decreasing 32.2% compared to the same period in 2025. This decline was driven by lower EasyPoint needle sales. Historically, international sales carry lower average selling prices than domestic sales. Management noted continued uncertainty regarding the timing of future international orders.

Operational Costs and Production

Cost of manufactured product decreased 34.7% year-over-year, largely tracking the decline in sales volume. Royalty expenses fell 20.8% due to lower gross sales. Operating expenses remained consistent between Q2 2026 and Q2 2025.

Tariff expenses totaled approximately $46 thousand in the second quarter of 2026, included within the cost of manufactured product. The company stated that these costs are lower than in prior periods due to mitigation efforts, including strategic sourcing and increased domestic production. Domestic production rose to 42.4% of units manufactured in the first six months of 2026, up from 38% in the same period last year.

A reduction in force implemented in April 2026 is expected to yield cost savings in future periods. However, management warned that tariffs may continue to materially impact costs going forward.

First Half Overview

For the six months ended June 30, 2026, the company reported a net loss of $1.4 million, compared to a net loss in the same period of 2025. The half-year results include the same $6.4 million gain on equity sales. Operating losses for the first half widened to $11.3 million from $9.8 million, driven by lower revenue and a 10.0% increase in operating expenses, primarily due to donation expense.

Unrealized losses on debt securities were $179 thousand for the quarter, reflecting decreased market values, while unrealized gains on debt securities for the six-month period were $13 thousand. The provision for income taxes was minimal at $1.8 thousand for the quarter and $3.7 thousand for the first half.

Retractable Technologies, Inc. has declared dividends for holders of its Series II Class B and Series III Class B Convertible Preferred Stock. The Board of Directors approved payments of $39,050.00 for Series II shareholders and $18,561.25 for Series III shareholders. The dividends have accrued at a rate of $1.00 per share per annum.

The dividends cover the period from April 1, 2026 through June 30, 2026. Shareholders of record as of the close of business on July 10, 2026 will receive the payment on July 20, 2026.

Dividend Details

Retractable Technologies manufactures and markets safety medical products, including VanishPoint syringes, blood collection devices, and IV catheter products designed to prevent needlestick injuries. The company also produces Patient Safe syringes to reduce the risk of bloodstream infections and the EasyPoint retractable needle for various medical applications.